company background image
TCON

TRACON Pharmaceuticals NasdaqCM:TCON Stock Report

Last Price

US$1.84

Market Cap

US$38.8m

7D

4.0%

1Y

-49.2%

Updated

06 Aug, 2022

Data

Company Financials +
TCON fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

TCON Stock Overview

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States.

TRACON Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TRACON Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.84
52 Week HighUS$4.49
52 Week LowUS$1.24
Beta1.47
1 Month Change-6.12%
3 Month Change-8.46%
1 Year Change-49.17%
3 Year Change-59.11%
5 Year Change-91.82%
Change since IPO-98.04%

Recent News & Updates

Shareholder Returns

TCONUS BiotechsUS Market
7D4.0%5.7%1.0%
1Y-49.2%-24.5%-12.9%

Return vs Industry: TCON underperformed the US Biotechs industry which returned -24.5% over the past year.

Return vs Market: TCON underperformed the US Market which returned -12.8% over the past year.

Price Volatility

Is TCON's price volatile compared to industry and market?
TCON volatility
TCON Average Weekly Movement11.6%
Biotechs Industry Average Movement12.9%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: TCON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: TCON's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200419Charles Theuerhttps://www.traconpharma.com

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.

TRACON Pharmaceuticals Fundamentals Summary

How do TRACON Pharmaceuticals's earnings and revenue compare to its market cap?
TCON fundamental statistics
Market CapUS$38.81m
Earnings (TTM)-US$33.08m
Revenue (TTM)US$346.00k

112.2x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TCON income statement (TTM)
RevenueUS$346.00k
Cost of RevenueUS$11.86m
Gross Profit-US$11.51m
Other ExpensesUS$21.57m
Earnings-US$33.08m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 10, 2022

Earnings per share (EPS)-1.57
Gross Margin-3,326.30%
Net Profit Margin-9,559.54%
Debt/Equity Ratio25.0%

How did TCON perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is TCON undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TCON?

Other financial metrics that can be useful for relative valuation.

TCON key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue69.3x
Enterprise Value/EBITDA-0.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does TCON's PB Ratio compare to its peers?

TCON PB Ratio vs Peers
The above table shows the PB ratio for TCON vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.9x
BYSI BeyondSpring
2.2x-14.8%US$58.8m
MBIO Mustang Bio
0.8x14.8%US$78.3m
SLDB Solid Biosciences
0.5x-9.8%US$85.6m
OGEN Oragenics
2.4x-13.1%US$43.1m
TCON TRACON Pharmaceuticals
13.9x-0.4%US$38.8m

Price-To-Book vs Peers: TCON is expensive based on its Price-To-Book Ratio (13.9x) compared to the peer average (0.9x).


Price to Earnings Ratio vs Industry

How does TCON's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: TCON is expensive based on its Price-To-Book Ratio (13.9x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is TCON's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TCON PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio13.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TCON's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of TCON when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TCON's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TCON's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is TRACON Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-0.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TCON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TCON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TCON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TCON's revenue (76.7% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: TCON's revenue (76.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TCON's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has TRACON Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


1.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TCON is currently unprofitable.

Growing Profit Margin: TCON is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TCON is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare TCON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TCON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).


Return on Equity

High ROE: TCON has a negative Return on Equity (-1185.52%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is TRACON Pharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TCON's short term assets ($17.3M) exceed its short term liabilities ($15.0M).

Long Term Liabilities: TCON's short term assets ($17.3M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: TCON has more cash than its total debt.

Reducing Debt: TCON's debt to equity ratio has reduced from 30.9% to 25% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TCON has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TCON has less than a year of cash runway if free cash flow continues to grow at historical rates of 3% each year.


Discover healthy companies

Dividend

What is TRACON Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TCON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TCON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TCON's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TCON's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TCON has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Charles Theuer (58 yo)

16.08yrs

Tenure

US$2,059,112

Compensation

Dr. Charles P. Theuer, M.D., Ph D., has been the President and Chief Executive Officer of Tracon Pharmaceuticals, Inc. since July 2006 and has been its Director of Tracon Pharmaceuticals, Inc. since June 2...


CEO Compensation Analysis

Compensation vs Market: Charles's total compensation ($USD2.06M) is above average for companies of similar size in the US market ($USD767.72K).

Compensation vs Earnings: Charles's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TCON's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: TCON's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TCON insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.


Top Shareholders

Company Information

TRACON Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: TRACON Pharmaceuticals, Inc.
  • Ticker: TCON
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$38.813m
  • Shares outstanding: 21.09m
  • Website: https://www.traconpharma.com

Number of Employees


Location

  • TRACON Pharmaceuticals, Inc.
  • 4350 La Jolla Village Drive
  • Suite 800
  • San Diego
  • California
  • 92122
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.